Chico Samuel Fernando Vargas, Diaz Daniel Alejandro Melendez, Contreras-Puentes Neyder
Department of Medicine, Rafael Nuñez University Corporation, Cartagena, Colombia.
J Neurosci Rural Pract. 2024 Apr-Jun;15(2):203-210. doi: 10.25259/JNRP_618_2023. Epub 2024 Mar 21.
Epilepsy poses a significant challenge in pediatric and adolescent populations, impacting not only seizures but also psychological and cognitive comorbidities, leading to higher mortality rates than the general population. Drug-refractory epilepsy, resistant to conventional treatments, affects a range of 7-20% of pediatric patients. The search for alternative therapies has led to exploring the therapeutic potential of L. compounds, particularly cannabidiol (CBD). Examine the use of CBD for treating drug-refractory epilepsy in children and young adults, summarizing existing evidence on its efficacy.
A systematic review, following Preferred Reporting Items for Systematic Reviews and Meta-analyses guidelines, assessed studies from 2018 to 2023, focusing on CBD's efficacy and safety for treatment-resistant epilepsy in pediatric and juvenile populations. The search spanned seven databases, and the studies underwent rigorous screening and data extraction.
Out of 6351 identified articles, eight were selected for review. The included studies reported positive outcomes, with CBD leading to a reduction in seizure frequency ranging from 50% to complete seizure freedom. Adverse effects were mostly mild and reversible, including drowsiness, diarrhea, and loss of appetite.
The CBD emerges as a promising tool for refractory epilepsy in pediatric patients, showing efficacy in reducing seizure frequency and improving overall quality of life. Despite mild and reversible adverse effects, CBD's benefits outweigh the risks. However, more research on long-term effects is needed to fully understand its implications.
癫痫对儿童和青少年群体构成重大挑战，不仅影响癫痫发作，还会导致心理和认知共病，致使死亡率高于普通人群。药物难治性癫痫对传统治疗有抗性，影响7%至20%的儿科患者。对替代疗法的探索促使人们研究L.化合物的治疗潜力，尤其是大麻二酚（CBD）。研究CBD用于治疗儿童和青年药物难治性癫痫的情况，总结其疗效的现有证据。
按照系统评价和Meta分析的首选报告项目指南进行系统评价，评估2018年至2023年的研究，重点关注CBD对儿科和青少年群体治疗抵抗性癫痫的疗效和安全性。检索了七个数据库，对研究进行了严格筛选和数据提取。
在6351篇已识别的文章中，选出八篇进行综述。纳入研究报告了积极结果，CBD使癫痫发作频率降低50%至完全无癫痫发作。不良反应大多轻微且可逆，包括嗜睡、腹泻和食欲不振。
CBD成为治疗儿科患者难治性癫痫的一种有前景的工具，在降低癫痫发作频率和改善总体生活质量方面显示出疗效。尽管有轻微且可逆的不良反应，但CBD的益处大于风险。然而，需要更多关于长期影响的研究来全面了解其影响。
